Posted by Michael Wonder on 23 Aug 2021
Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of Korsuva (difelikefalin) injection for the treatment of moderate to severe pruritus in hemodialysis patients
23 August 2021 - Promotional launch of Korsuva injection in the U.S. is expected in Q1 2022, with reimbursement in H1 2022.
Cara Therapeutics and Vifor Pharma today announced that the U.S. FDA has approved Korsuva (difelikefalin) for injection for the treatment of moderate to severe pruritus associated with chronic kidney disease in adults undergoing haemodialysis.
